Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F17%3A00075959" target="_blank" >RIV/65269705:_____/17:00075959 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/17:00097523
Result on the web
<a href="https://link.springer.com/article/10.1007/s00262-016-1932-4" target="_blank" >https://link.springer.com/article/10.1007/s00262-016-1932-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s00262-016-1932-4" target="_blank" >10.1007/s00262-016-1932-4</a>
Alternative languages
Result language
angličtina
Original language name
Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells
Original language description
The natural adjuvant properties of bacterial ghosts (BGs) lie within the presence of intact pathogen-associated molecular patterns on their surface. BGs can improve the direct delivery, natural processing and presentation of target antigens within dendritic cells (DCs). Moreover, sensitization of human DCs by cancer cell lysate (oncolysate)-loaded BGs in the presence of IFN-alpha and GM-CSF enhanced DC maturation as indicated by an increased expression of maturation markers and costimulatory molecules, higher production of IL-12p70 and stimulation of significantly increased proliferation of both autologous CD4(+) and CD8(+) T cells compared to DCs matured in the presence of purified lipopolysaccharide. The induced T cells efficiently recognized oncolysate-derived tumor-associated antigens expressed by cancer cells used for the production of oncolysate. Our optimized one-step simultaneous antigen delivery and DC maturation-inducing method emerges as a promising tool for the development and implementation of next-generation cellular cancer immunotherapies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30200 - Clinical medicine
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Immunology, Immunotherapy
ISSN
0340-7004
e-ISSN
—
Volume of the periodical
66
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
149-159
UT code for WoS article
000394982400002
EID of the result in the Scopus database
2-s2.0-84995752930